Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market
Sun Pharmaceutical enters into merger agreement with Taro Pharmaceutical
We are advising Sun Pharma on the transaction
Roche $295 million acquisition of LumiraDx's point of care technology platform
We are advising Roche on the acquisition
OPKO Health $230 million convertible senior notes offering
The 3.75% convertible notes are due 2029
Auna $550 million secured term loan refinancing
We advised Auna on the transaction
Solid Biosciences $109 million private placement
The PIPE includes common stock and pre-funded warrants
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Air Methods emerges from chapter 11
We advised the ad hoc group that negotiated and backstopped the restructuring
HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing
GSK exclusive license agreement for HS-20093 with Hansoh Pharma
We advised GSK on the transaction